Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Study (n=113) found that, a risk adapted DA-EPOCH-R strategy (low risk = 3 cycles without CNS prophylaxis, high risk = six cycles including intrathecal prophylaxis) was effective and well tolerated. Event free survival was 100% in high risk and 82.1% in low risk patients.


Journal of Clinical Oncology